Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q1
Sell
-13,089
Closed -$326K 198
2025
Q4
$326K Sell
13,089
-21
-0.2% -$530 0.08% 151
2025
Q3
$334K Buy
+13,110
New +$324K 0.08% 151
2025
Q2
Sell
-11,423
Closed -$289K 206
2025
Q1
$289K Buy
11,423
+2,046
+22% +$53.5K 0.08% 163
2024
Q4
$240K Sell
9,377
-3,533
-27% -$95.8K 0.07% 188
2024
Q3
$374K Sell
12,910
-30
-0.2% -$875 0.12% 124
2024
Q2
$362K Buy
+12,940
New +$356K 0.11% 140
2023
Q3
$448K Sell
13,513
-523
-4% -$18.5K 0.26% 64
2023
Q2
$515K Buy
14,036
+98
+0.7% +$3.81K 0.3% 55
2023
Q1
$569K Sell
13,938
-12,439
-47% -$537K 0.34% 48
2022
Q4
$4.77M Buy
26,377
+12,429
+89% +$596K 3.07% 6
2022
Q3
$610K Buy
13,948
+38
+0.3% +$1.85K 0.44% 41
2022
Q2
$729K Buy
+13,910
New +$709K 0.5% 40

Other funds holding PFE

Tradewinds LLC's PFE Position: Q1 2026 in Review

Tradewinds LLC sold out of Pfizer (PFE) in Q1 2026, closing a stake of 13,089 shares — an estimated $326K sold.

Tradewinds LLC first reported a position in PFE in Q2 2022 and held it in 12 quarters. The position peaked at $4.77M in Q4 2022. 2,939 funds tracked by Wall St. Rank hold PFE as of Q1 2026.

  • Tradewinds LLC reported no remaining Pfizer position as of Q1 2026 after selling out during the quarter.
  • Tradewinds LLC sold 13,089 Pfizer shares in Q1 2026, an estimated $326K.
  • Tradewinds LLC first reported a position in Pfizer in Q2 2022 and held it in 12 quarters.
  • Tradewinds LLC's Pfizer position peaked at $4.77M in Q4 2022.
  • 2,939 funds tracked by Wall St. Rank held Pfizer as of Q1 2026.

Based on Tradewinds LLC's 13F filing for Q1 2026, filed 4 May 2026.